Your session is about to expire
← Back to Search
Cancer Vaccine
NM32-2668 for Advanced Cancer
Phase 1
Recruiting
Research Sponsored by Numab Therapeutics AG
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
No Placebo-Only Group
Summary
This trial is testing a new drug called NM32-2668 in adult patients with advanced solid tumors. The main goals are to check the safety and effectiveness of the drug, find the highest safe dose
Who is the study for?
Adults with certain advanced solid tumors, including various cancers like endometrial, melanoma, ovarian, kidney, breast cancer and more. Participants must meet specific health criteria to join.
What is being tested?
NM32-2668 is being tested for safety and effectiveness in treating selected advanced solid tumors. This early-phase trial will determine the best dose and gather initial data on how well it works.
What are the potential side effects?
Since this is a first-in-human study of NM32-2668, potential side effects are not yet fully known but may include typical drug reactions such as nausea, fatigue, or allergic responses.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 5 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
Treatment Details
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: NM32-2668Experimental Treatment1 Intervention
Find a Location
Who is running the clinical trial?
Numab Therapeutics AGLead Sponsor
2 Previous Clinical Trials
178 Total Patients Enrolled